OncoC4 takes its Siglec-10 bet into the clinic
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.